Alissa Visram, Annika Werly, Carsten Mueller-Tidow, Elias K.Mai, Hartmut Goldschmidt, Kosima Zuern, Marc S. Raab, Mareike Hampel, Sophia K. Schmidt, Thomas Hielscher
A study of 447 patients with Smoldering multiple myeloma (SMM) reveals that almost one third (31 %) progressed to active Multiple myeloma (MM) over a median follow-up of 5.8 years. Among these, 43 % developed bone lesions, 34 % showed a free light chain ratio ≥ 100, 23 % had multiple focal lesions on MRI and 20 % developed anemia — underlining the importance of regular MRI and biomarker monitoring for early intervention.
Fig. 1: MDEs in patients with smoldering multiple myeloma according to high, low/intermediate or unknown risk status.
